Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

58.44
+0.11000.19%
Post-market: 58.26-0.1800-0.31%19:30 EDT
Volume:2.37M
Turnover:139.25M
Market Cap:14.48B
PE:18.38
High:59.27
Open:58.47
Low:57.88
Close:58.33
52wk High:61.14
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.08
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.85
PE(LYR):21.02

Loading ...

EXEL Industries Updates Share Capital and Voting Rights for August 2026

TIPRANKS
·
Sep 03

Exelixis to Webcast Fireside Chats at Wells Fargo Healthcare Conference

Reuters
·
Sep 02

Exelixis Secures Key Patent Victory, Extends Exclusivity

TIPRANKS
·
Sep 01

Exelixis Wins Appeal in Patent Case Against MSN Laboratories

MT Newswires Live
·
Sep 01

Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment

TIPRANKS
·
Sep 01

Exelixis Wins Federal Circuit Ruling Upholding Cabometyx Crystalline Salt Patents

Reuters
·
Sep 01

Exelixis - U.S. Court of Appeals for the Federal Circuit Affirms Key Portion of 2024 Judgment in Exelixis' Favor

THOMSON REUTERS
·
Sep 01

Exelixis Announces Update on Patent Litigation Trial Appeal with Msn Laboratories

THOMSON REUTERS
·
Sep 01

Exelixis - Msn May Launch Generic Cabozantinib in U.S. no Earlier than January 15, 2030

THOMSON REUTERS
·
Sep 01

13D Filings

Dow Jones
·
Aug 22

EXEL INDUSTRIES Updates Market on Share Capital and Voting Rights

TIPRANKS
·
Aug 20

BMO starts Exelixis at Market Perform into patent cliff

TIPRANKS
·
Aug 19

Exelixis Director Mary C Beckerle Disposes of 9,812 Shares Worth $526,908.92

Reuters
·
Aug 13

Exelixis (EXEL) Earnings Strength Meets Lower Guidance As Valuation Comes Back Into View

Simply Wall St.
·
Aug 12

Exelixis Earnings Call: Cabo Strength, Zanza Awaited

TIPRANKS
·
Aug 08

U.S. Research Roundup-Airbnb, Expedia Group, Parker-Hannifin

Reuters
·
Aug 07

Guggenheim Keeps Their Hold Rating on Exelixis (EXEL)

TIPRANKS
·
Aug 07

Exelixis Inc : Leerink Partners Cuts to Market Perform from Outperform

THOMSON REUTERS
·
Aug 07

Leerink downgrades Exelixis to Market Perform following Q2 results

TIPRANKS
·
Aug 07

Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial

TIPRANKS
·
Aug 07